A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...

The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults ...

The US Food and Drug Administration has approved the use of lerodalcibep (Lerochol) to reduce LDL cholesterol alongside ...

LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients ...

The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, for lowering LDL cholesterol in adults ...

FDA has announced the approval of LIB Therapeutics’ Lerochol (lerodalcibep-liga) for subcutaneous (SC) use as an adjunct to ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...

A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...

Heart doctors are capturing images of the inside of heart arteries, helping them watch plaque respond to cholesterol drugs in ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...